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Purpose: To establish the efficacy and safety of intravitreal bevacizumab in reducing iris and 
anterior chamber angle neovascularization and managing neovascular glaucoma.
Design: Prospective interventional case series.
Patient and methods: Eleven eyes of 11 patients with iris and anterior chamber angle 
neovascularization with refractory intraocular pressure were treated with intravitreal injection 
of 1.25 mg bevacizumab (Avastin®). The study group included eight males and three females 
aged 23 to 77 years (average, 62 years). Out of the 11 cases, five had proliferative diabetic 
retinopathy, of whom two had undergone vitrectomy for tractional retinal detachment and vitreous 
hemorrhage, and six were secondary to ischemic central retinal vein occlusion (CRVO). All 
patients were followed for eight to 16 months (average, 10 months).
Results: Iris and anterior chamber angle neovascularization receded in all eyes after one to three 
injections at monthly intervals. In five eyes, neovascularization recurred during the follow-up 
period. The intraocular pressure normalized in one eye. Four eyes were controlled with anti-
glaucoma drops. A cyclodestructive procedure was required in two eyes. An Ahmet drainage 
valve was implanted in four eyes, including one controlled with additional antiglaucoma drops 
and one in which the intraocular pressure remained high while on maximum antiglaucoma 
medication and a cyclodestructive procedure was scheduled.
Conclusions: Bevacizumab appears to be effective in reducing iris and anterior chamber 
angle neovascularization and is likely to extend our therapeutic options in the management of 
neovascular glaucoma.
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Retinal ischemia and vascular endothelial growth factor (VEGF) have been implicated 
as major angiogenic stimuli responsible for retinal neovascularization. In addition, 
they are implicated in the growth of abnormal blood vessels on iris, anterior chamber 
angle, and in the development of neovascular glaucoma.
The standard treatment for iris and anterior angle neovascularization is panreti-
nal photocoagulation (PRP), whereas in cases with intraocular pressure (IOP) rise, 
therapeutic options include PRP with topical antiglaucoma drops, per os carbonic 
anhydrase inhibitors, tube drainage procedures, photodynamic therapy,1 or cyclode-
structive procedures.
Bevacizumab (Avastin®; Genentech/Roche), a humanized antibody to VEGF, 
was recently reported to be of benefit in retinal and iris neovascularization due to Clinical Ophthalmology 2009:3 686
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diabetic retinopathy,2–5 in iris neovascularization due to 
central retinal vein occlusion (CRVO),5,6 central retinal artery 
occlusion,6 and managing IOP in CRVO,7 anterior ischemic 
syndrome,8 and neovascular glaucoma of various etiologies.9 
In addition, intracameral bevacizumab followed by trabecu-
lectomy reportedly results in good surgical outcomes.10
This case series demonstrates the effectiveness and safety 
of intravitreal bevacizumab in the management of anterior 
chamber and iris neovascularization and as an adjunct treat-
ment of neovascular glaucoma of various etiologies.
Patients and methods
Eleven eyes of 11 consecutive patients with iris and anterior 
chamber angle neovascularization and refractory IOP while 
on maximum antiglaucoma medication, were treated with 
intravitreal injections of 0.05 ml (1.25 mg) bevacizumab 
(Avastin®). Retreatment was based on biomicroscopic 
evidence of residual iris or anterior chamber neovascu-
larization at monthly intervals until the disappearance of 
neovascularization.
The study group included eight male and three female 
patients, aged 23 to 77 years (average, 62 years). Out of the 
11 cases, five had proliferative diabetic retinopathy, of whom 
two had undergone vitrectomy for tractional retinal detach-
ment and vitreous hemorrhage, and six were secondary to 
ischemic CRVO.
The average IOP on presentation was 40.8 mmHg 
(standard deviation [SD] = 5.3) while on maximum anti-
glaucoma medication. Seven patients had undergone prior 
panretinal laser photocoagulation (PRP), of whom three 
had additional PRP after bevacizumab injections. One 
additional patient commenced PRP after bevacizumab treat-
ment, whereas the remaining three patients were not able 
to undergo any PRP because of dense vitreous hemorrhage 
(Table 1).
The patients were followed monthly for eight to 16 months 
(average, 10 months; SD = 2.6).
The study was approved by the University of Athens 
institutional ethical committee on the basis of existing 
literature. Each patient was informed of the study purposes, 
the alternative therapeutic options, the natural history of the 
disease, the off-label use of bevacizumab and signed the 
relative consent form. All the recommendations for intravitreal 
injections were followed.11
Results
In seven eyes, iris and anterior chamber angle neovascular-
ization biomicroscopically disappeared following the first 
injection, in one eye following the second one, whereas the 
other three eyes required a third injection.
The average IOP at the end of the follow-up period was 
16.1 mmHg (range 10 to 32 mmHg). The patient who had had 
two injections, had his IOP controlled without further treatment. 
In four patients, the IOP was normalized with the use of 
antiglaucoma drops. In two patients, the IOP remained refractory 
and necessitated a cyclodestructive procedure. Implantation of an 
Ahmet drainage valve was completed in four patients, of whom 
two needed additional topical medication. In one of the latter 
two, the IOP remained high despite maximum antiglaucoma 
medication and a cyclodestructive procedure was scheduled.
Reappearance of iris and angle neovascularization during 
the follow-up period was noted in five eyes. Noteworthy, 
further laser treatment was not possible in any of these eyes 
(Table 2).
No ophthalmic or systemic complications attributable 
to intravitreal injections were recorded, except insignificant 
conjunctival hematoma at injection site in some cases 
(Figures 1, 2).
Discussion
Intraocular bevacizumab has been tried as an adjunct 
treatment modality in anterior chamber neovascularization of 
various etiologies2–6 and the short term efficacy of intraocular 
injection on iris neovascularization and IOP is well proven.12–14 
Figure 1 Case 1 A) On presentation and B) after first injection. Regression of iris 
neovascularization.
Figure 2 Case 3 A) On presentation, iris neovascularization. After three-month 
intravitreal injections of bevacizumab neovascularization disappears. B) reappearance 
of neovascularization six months later.Clinical Ophthalmology 2009:3 687
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In a retrospective case series12 that included six eyes of three 
patients, all eyes manifested marked regression up to complete 
disappearance of iris and angle neovascularization after a 
single intravitreal injection. In three out of six eyes IOP 
decreased, whereas in the remaining patients IOP remained 
refractory and cyclophotocoagulation was decided. In 
another retrospective study including 41 eyes with significant 
follow-up (13.3 months), the authors concluded that intravitreal 
bevacizumab is well-tolerated, effectively stabilizing iris 
neovascularization and controlling IOP in patients with iris 
neovascularization alone or early-stage neovascular glaucoma 
without angle closure. In advanced neovascular glaucoma, 
intravitreal bevacizumab could not control IOP but could be 
used adjunctively to improve subsequent surgical results.15
In our study, the intravitreal administration of bevacizumab 
in monthly intervals (one to three injections) resulted in 
considerable regression of iris and anterior chamber angle 
neovascularization. The results seem to be more favorable 
when “sufficient” elimination of retinal ischemia is attained, 
as was apparently the case in patient 1 following the reat-
tachment of the retina. Iris neovascularization reappeared 
in all three eyes without laser treatment and in only two out 
of eight eyes that underwent PRP before or after intravitreal 
injection (Table 2).
Control of the IOP required additional medical treatment 
or surgical intervention in 10 out of 11 eyes. As a general 
trend, regression of iris neovascularization resulted in 
management of IOP without further treatment or with topical 
Table 1 Patient data on presentation and treatment
Case No Age Gender Eye Etiology IOP on presentation 
(mmHg)
Laser 
before
Anterior synechia 
(quadrants)
Avastin® 
(injections)
1 43 Male Os DM/Vit 45 + - ++
2 63 Male Os CrVO 42 + 2/4 +
3 70 Female OD CrVO 32 4/4 +++
4 76 Male Os CrVO 38 + 4/4 +++
5 59 Female OD DM 42 + 3/4 +
6 23 Female OD DM 38 + - +
7 72 Male Os CrVO 32 4/4 +
8 69 Male Os CrVO 45 2/4 +
9 60 Male OD DM/Vit 48 + 4/4 +
10 70 Male OD CrVO 42 4/4 +++
11 77 Male OD DM 45 + 1/4 +
Average 62 40.82
sD 16.11 5.29
Table 2 Follow up and final results
Case No Age Laser after Follow-up (months) Iris neovascularization  Final treatment Final IOP (mmHg)
1 43 16 Nothing 14
2 63 13 Drops 16
3 70 11 reappears Cyclodestruction 10
4 76 10 reappears Ahmet  12
5 59 + 10 Drops 18
6 23 + 8 Drops 17
7 72 10 reappears Ahmet + drops 12
8 69 + 8 Ahmet 14
9 60 8 reappears Ahmet + drops 32
10 70 8 reappears Cyclodestruction 12
11 77 + 8 Drops 17
Average 62 10 16.11
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medical medication only (five of six cases), whereas recurrent 
neovascularization additionally required invasive treatments 
(valve implantation in two eyes and cyclodestruction in three 
eyes). The presence of extensive anterior synechiae predisposed 
to uncontrolled IOP that also demanded surgical intervention. 
Younger patients tended to respond better to treatment and 
develop less anterior synechiae (Tables 1 and 2).
The absence of ocular side effects or systemic complica-
tions is in agreement with the findings of a related metanalysis 
study comprising 127 eyes, which estimated that ophthalmic 
complications were under 0.78% without reported systemic 
complications.14
In conclusion, intraocular bevacizumab targets the 
basic pathophysiological mechanism of retinal and anterior 
chamber neovascularization and may serve as an adjunct 
to PRP in cases of neovascular glaucoma. In our study, 
anti-VEGF treatment enabled continuation of PRP in one 
eye and initiation of PRP in three eyes (Table 2), reducing 
neovascularization until vitreous hemorrhage subsided and 
iris became more pliable to mydriasis. In this context, intra-
ocular bevacizumab appears to be effective in reducing iris 
and anterior chamber angle neovascularization and has a role 
in the management of neovascular glaucoma.
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